ArticleOphthalmology science2026
Assessing Polypoidal Choroidal Vasculopathy-Related OCT Features in the TENAYA and LUCERNE Trials.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe OCT features associated with polypoidal choroidal vasculopathy (PCV) in the TENAYA and LUCERNE clinical trial cohorts. Design: Imaging analysis within 2 multinational, double-masked, randomized controlled phase III trials. Subjects: Participants with treatment-naïve neovascular age-related macular degeneration enrolled in TENAYA and LUCERNE with baseline OCT and in a subset, baseline indocyanine green angiography (ICGA). Methods: Previously described OCT features associated with PCV were evaluated among 1329 participants. Two major OCT features were evaluated (sharp-peaked pigment epithelial detachment [SPED] and sub-retinal pigment epithelium ring-like lesion) to determine the occurrence of OCT-defined PCV. Subretinal fluid, intraretinal fluid (IRF), and hyperreflective material (HRM), were compared between OCT-defined PCV and non-PCV eyes. A sensitivity analysis was performed in the subset of eyes with available ICGA to assess concordance between OCT and ICGA-confirmed PCV. Main Outcome Measures: Occurrence of OCT-defined PCV and distribution of OCT-based disease activity biomarkers by PCV status. Results: Using the 2 major OCT criteria, 88 (6.7%) of eyes were classified as OCT-defined PCV. Fewer OCT-defined PCV eyes had IRF and HRM compared with non-PCV eyes (27.3% vs. 45.5%, Conclusions: Using 2 Asia-Pacific Ocular Imaging Society major OCT features, OCT-based diagnostic strategy may help triage or screen for PCV when ICGA is unavailable. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.